uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2025-32-4-19-29uzspbgmu-1215Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESВысокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при системной аутоиммунной патологии: фокус на системную склеродермиюHigh-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in systemic autoimmune pathology: focus on systemic sclerosishttps://orcid.org/0000-0002-9850-1107СагановаЕ. С.SaganovaE. S.

Саганова Елена Сергеевна, кандидат медицинских наук, зав. нефрологическим отделением №1 клиники «НИИ Нефрологии» НКИЦ, врач-нефролог, врач-ревматолог, доцент кафедры «Нефрологии и диализа» ФПО, ассистент кафедры внутренних болезней с клиникой

AuthorID: 819980;

Scopus Author ID: 55817583000

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Saganova Elena S., Cand. of Sci. (Med.), Head of the Nephrological Department № 1 of the Clinic of the Research Institute of Nephrology of the Scientific and Clinical Research Center, Nephrologist, Rheumatologist, Associate Professor of the Department of Nephrology and Dialysis of the Faculty of Postgraduate Education

AuthorID: 819980;

Scopus Author ID: 55817583000

6-8, L’va Tolstogo str., Saint Petersburg, 197022

nephrolog1985@gmail.comhttps://orcid.org/0000-0001-8699-2482ПолушинА. Ю.PolushinA. Yu.

Полушин Алексей Юрьевич, кандидат медицинских наук, доцент, руководитель научно-клинического центра трансплантации и клеточной терапии при аутоиммунных и нейродегенеративных заболеваниях, доцент кафедры неврологии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Polushin Aleksei Yu., Cand. of Sci. (Med.), Associate Professor, Head of the Scientific and Clinical Center for Transplantation and Cell Therapy in Autoimmune and Neurodegenerative Diseases, Associate Professor of the Department of Neurology

6-8, L’va Tolstogo str., Saint Petersburg, 197022

https://orcid.org/0000-0002-3881-4486ЗаляловЮ. Р.ZalyalovIu. R.

Залялов Юрий Ринатович, кандидат медицинских наук, врач-гематолог, зав. отделением химиотерапии и трансплантации костного мозга при онкологических и аутоиммунных заболеваниях НКЦ

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Zalyalov Iurii R., Cand. of Sci. (Med.), Hematologist, Head of the Department of Chemotherapy and Bone Marrow Transplantation in Oncological and Autoimmune Diseases of the Scientific and Clinical Center

6-8, L’va Tolstogo str., Saint Petersburg, 197022

https://orcid.org/0000-0002-4544-2967КуликовА. Н.KulikovA. N.

Куликов Александр Николаевич, доктор медицинских наук, профессор, зав. кафедрой пропедевтики внутренних болезней с клиникой, заведующий кафедрой функциональной диагностики, директор НКИЦ

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Kulikov Aleksandr N., Dr. of Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal Diseases with the Clinic, Head of the Department of Functional Diagnostics, Director of the Scientific and Clinical Research Center

6-8, L’va Tolstogo str., Saint Petersburg, 197022

https://orcid.org/0000-0002-9589-4136КулагинА. Д.KulaginA. D.

Кулагин Александр Дмитриевич, доктор медицинских наук, директор НИИ детской онкологии, гематологии и трансплантологии имени Р. М. Горбачевой, заведующий кафедрой гематологии, трансфузиологии и трансплантологии с курсом детской онкологии ФПО им. профессора Б. В. Афанасьева

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Kulagin Aleksandr D., Cand. of Sci. (Med.), Director of the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Head of the Department of Hematology, Transfusiology and Transplantology with the course of Pediatric Oncology of the Faculty of Postgraduate Education named after Professor B. V. Afanasiev

6-8, L’va Tolstogo str., Saint Petersburg, 197022

Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. ПавловаРоссияPavlov UniversityRussian Federation2025080420263241929Copyright © Саганова Е.С., Полушин А.Ю., Залялов Ю.Р., Куликов А.Н., Кулагин А.Д., 20262026Саганова Е.С., Полушин А.Ю., Залялов Ю.Р., Куликов А.Н., Кулагин А.Д.Saganova E.S., Polushin A.Y., Zalyalov I.R., Kulikov A.N., Kulagin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/1215

В мире отмечается рост заболеваемости аутоиммунными болезнями. Системная склеродермия (ССД) чаще встречается у лиц молодого возраста, характеризуясь обширным прогрессирующим фиброзным поражением кожи и других органов, а быстро прогрессирующая диффузная форма ССД в 30 % случаев может приводить к краткосрочному летальному исходу. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических столовых клеток (ВИСТ-АТГСК) оказывает множественные иммуноопосредованные эффекты, которые могут привести к уменьшению клинических проявлений и улучшению прогноза у пациентов с ССД. Метод при ССД применяется с 1997 г. В рамках регистра Европейского общества по трансплантации крови и костного мозга выполнено около 900 процедур трансплантации при ССД. В представленной работе проанализированы результаты рандомизированных клинических исследований (ASSIST, ASTIS, SCOT) применения ВИСТ-АТГСК при ССД: представлены характеристики групп пациентов, режимы кондиционирования, эффективность в сравнении со стандартными методами терапии. Также представлены критерии и схема отбора пациентов, показания и противопоказания для проведения процедуры. Представленные данные могут быть использованы для последующего обоснования расширения возможностей оказания помощи пациентам с ССД в Российской Федерации.

The incidence of autoimmune diseases is increasing worldwide. Systemic sclerosis (SSc) is more common in young adults and is characterized by extensive progressive fibrotic lesions of the skin and other organs. The rapidly progressive diffuse form of SSc can lead to short-term mortality in 30% of cases. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) has multiple immune-mediated effects that can reduce clinical manifestations and improve prognosis in patients with SSc. The method has been used for SSc since 1997. Approximately 900 transplant procedures for SSc have been performed within the registry of the European Society for Blood and Marrow Transplantation (EBMT). This paper analyzes the results of randomized clinical trials (ASSIST, ASTIS, SCOT) using HDIT-AHSCT in SSc. It presents patient group characteristics, conditioning regimens, and efficacy compared to standard therapies. The criteria and patient selection process, as well as indications and contraindications for the procedure, are also presented. This information can be used to further justify the expansion of care options for patients with SSc in the Russian Federation.

ВИСТ-АТГСКвысокодозная иммуносупрессивная терапиясистемная склеродермиясистемный склерозгемопоэтические стволовые клеткиаутологичная трансплантациярефрактерная форма склеродермыHDIT-AHSCThigh-dose immunosuppressive therapysystemic sclerodermasystemic sclerosishematopoietic stem cellsautologous transplantationrefractory sclerodermaReferencesWang L., Wang F. S., Gershwin M. E. Human autoimmune diseases: a comprehensive update // J Intern Med. – 2015. – Vol. 278, № 4. – P. 369–95. https://doi.org/10.1111/joim.12395.Wang L., Wang F. S., Gershwin M. E. Human autoimmune diseases: a comprehensive update // J Intern Med. 2015;278(4):369–95. https://doi.org/10.1111/joim.12395.Scherlinger M., Mertz P., Sagez F. et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014 // Autoimmun Rev. – 2020. – Vol. 19, № 6. – P. 102531. https://doi.org/10.1016/j.autrev.2020.102531.Scherlinger M., Mertz P., Sagez F. et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014 // Autoimmun Rev. 2020;19(6):102531. https://doi.org/10.1016/j.autrev.2020.102531.Lerner A., Jeremias P., Matthias T. The world incidence and prevalence of autoimmune diseases is increasing // International Journal of Celiac Disease. – 2015. – Vol. 3, № 4. – P. 151–155. https://doi.org/10.12691/ijcd-3-4-8.Lerner A., Jeremias P., Matthias T. The world incidence and prevalence of autoimmune diseases is increasing // International Journal of Celiac Disease. 2015;3(4):151–155. https://doi.org/10.12691/ijcd-3-4-8.Miller F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention // Curr Opin Immunol. – 2023. – Vol. 80. – P. 102266. https://doi.org/10.1016/j.coi.2022.102266.Miller F. W. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention // Curr Opin Immunol. 2023;80:102266. https://doi.org/10.1016/j.coi.2022.102266.Cooper G. S., Bynum M. L., Somers E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases // J Autoimmun. – 2009. – Vol. 33, № 3–4. – P. 197–207. https://doi.org/10.1016/j.jaut.2009.09.008.Cooper G. S., Bynum M. L., Somers E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases // J Autoimmun. 2009;33(3–4):197–207. https://doi.org/10.1016/j.jaut.2009.09.008.Pisetsky D. S. Pathogenesis of autoimmune disease // Nat Rev Nephrol. – 2023. – Vol. 19, № 8. – P. 509–524. https://doi.org/10.1038/s41581-023-00720-1.Pisetsky D. S. Pathogenesis of autoimmune disease // Nat Rev Nephrol. 2023;19(8):509–524. https://doi.org/10.1038/s41581-023-00720-1.Swart J. F., Delemarre E. M., van Wijk F. et al. Haematopoietic stem cell transplantation for autoimmune diseases // Nat Rev Rheumatol. – 2017. – Vol. 13, № 4. – P. 244–256. https://doi.org/10.1038/nrrheum.2017.7.Swart J. F., Delemarre E. M., van Wijk F. et al. Haematopoietic stem cell transplantation for autoimmune diseases // Nat Rev Rheumatol. 2017;13(4):244–256. https://doi.org/10.1038/nrrheum.2017.7.Smilek D. E., Ehlers M. R., Nepom G. T. Restoring the balance: immunotherapeutic combinations for autoimmune disease // Dis Model Mech. – 2014. – Vol. 7, № 5. – P. 503–13. https://doi.org/10.1242/dmm.015099.Smilek D. E., Ehlers M. R., Nepom G. T. Restoring the balance: immunotherapeutic combinations for autoimmune disease // Dis Model Mech. 2014;7(5):503–13. https://doi.org/10.1242/dmm.015099.Alexander T., Farge D., Badoglio M. et al. Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms // J Autoimmun. – 2018. – Vol. 92. – P. 35–46. https://doi.org/10.1016/j.jaut.2018.06.002.Alexander T., Farge D., Badoglio M. et al. Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms // J Autoimmun. 2018;92:35–46. https://doi.org/10.1016/j.jaut.2018.06.002.Alexander T., Greco R., Snowden J. A. Hematopoietic stem cell transplantation for autoimmune disease // Annu Rev Med. – 2021. – Vol. 72. – P. 215–228. https://doi.org/10.1146/annurev-med-070119-115617.Alexander T., Greco R., Snowden J. A. Hematopoietic stem cell transplantation for autoimmune disease // Annu Rev Med. 2021;72:215–228. https://doi.org/10.1146/annurev-med-070119-115617.Полушин А. Ю., Залялов Ю. Р., Тотолян Н. А. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при рассеянном склерозе: перспективы снижения рисков // Анналы клинической и экспериментальной неврологии. – 2022. – Т. 16, № 3. – С. 53–64. https://doi.org/10.54101/ACEN.2022.3.7.Polushin A. Yu., Zalyalov Y. R., Totolyan N. A. et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: approaches to risk management // Annals of Clinical and Experimental Neurology. 2022;16(3):53–64. (In Russ.). https://doi.org/10.54101/ACEN.2022.3.7.Duarte R. F., Labopin M., Bader P. et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 // Bone Marrow Transplant. – 2019. – Vol. 54, № 10. – P. 1525–1552. https://doi.org/10.1038/s41409-019-0516-2.Duarte R. F., Labopin M., Bader P. et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 // Bone Marrow Transplant. 2019;54(10):1525–1552. https://doi.org/10.1038/s41409-019-0516-2.Afanasyev B. V., Afanasyeva K. S., Barabanshchikova M. V. et al. Indications for hematopoietic stem cell transplantation. 2nd Edition. Based on EBMT Recommendations of 2019 // Cellular Therapy and Transplantation. – 2019. – Vol. 8, № 4. – P. 101–145. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.Afanasyev B. V., Afanasyeva K. S., Barabanshchikova M. V. et al. Indications for hematopoietic stem cell transplantation. 2nd Edition. Based on EBMT Recommendations of 2019 // Cellular Therapy and Transplantation. 2019;8(4):101–145. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.Laureys G., Willekens B., Vanopdenbosch L. et al. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis // Acta Neurol Belg. – 2018. – Vol. 118, № 2. – P. 161–168. https://doi.org/10.1007/s13760-018-0905-0.Laureys G., Willekens B., Vanopdenbosch L. et al. A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis // Acta Neurol Belg. 2018;118(2):161–168. https://doi.org/10.1007/s13760-018-0905-0.Burman J., Tolf A., Hägglund H., Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases // J Neurol Neurosurg Psychiatry. – 2018. – Vol. 89, № 2. – P. 147–155. https://doi.org/10.1136/jnnp-2017-316271.Burman J., Tolf A., Hägglund H., Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases // J Neurol Neurosurg Psychiatry. 2018;89(2):147–155. https://doi.org/10.1136/jnnp-2017-316271.Полушин А. Ю., Залялов Ю. Р., Тотолян Н. А. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при рассеянном склерозе: современный взгляд на метод (обзор литературы) // Ученые записки Санкт-Петербургского государственного медицинского университета имени академикаИ. П. Павлова. – 2021. – Т. 28, № 4. – С. 9–21. https://doi.org/10.24884/1607-4181-2021-28-4-9-21.Polushin A. Yu., Zalyalov Yu. R., Totolyan N. A. et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: a modern view of the method (review of literature) // The Scientific Notes of Pavlov University. 2021;28(4):9–21. (In Russ.). https://doi.org/10.24884/1607-4181-2021-28-4-9-21.Tyndall A., Black C., Finke J. et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation // Lancet. – 1997. – Vol. 349, № 9047. – P. 254. https://doi.org/10.1016/s0140-6736(05)64864-7.Tyndall A., Black C., Finke J. et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation // Lancet. 1997;349(9047):254. https://doi.org/10.1016/s0140-6736(05)64864-7.Ганич Е. Г., Щукина О. Б., Полушин А. Ю. и др. Высокодозная иммуносупрессивная терапия с аутологичной трансплантацией гемопоэтических стволовых клеток при болезни Крона: обзор литературы // Новые Санкт-Петербургские врачебные ведомости. – 2024. – № 2. – P. 11–24. https://doi.org/10.24884/1609-2201-2024-103-2-11-24.Ganich E. G., Shchukina O. B., Polushin A. Yu. et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in Crohn disease: literature review // New St. Petersburg Medical Records. 2024;(2):11–24. (In Russ.). https://doi.org/10.24884/1609-2201-2024-103-2-11-24.Sykes M., Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation // Nature. – 2005. – Vol. 435, № 7042. – P. 620–7. https://doi.org/10.1038/nature03728.Sykes M., Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation // Nature. 2005;435(7042):620–7. https://doi.org/10.1038/nature03728.Tyndall A., Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions // Clin Exp Immunol. – 2005. – Vol. 141, № 1. – P. 1–9. https://doi.org/10.1111/j.1365-2249.2005.02806.x.Tyndall A., Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions // Clin Exp Immunol. 2005;141(1):1–9. https://doi.org/10.1111/j.1365-2249.2005.02806.x.Farge D., Marolleau J. P., Zohar S. et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study // Br J Haematol. – 2002. – Vol. 119, № 3. – P. 726–39. https://doi.org/10.1046/j.1365-2141.2002.03895.x.Farge D., Marolleau J. P., Zohar S. et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study // Br J Haematol. 2002;119(3):726–39. https://doi.org/10.1046/j.1365-2141.2002.03895.x.Snowden J. A., Sharrack B., Akil M. et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist // Clin Med (Lond). – 2018. – Vol. 18, № 4. – P. 329–334. https://doi.org/10.7861/clinmedicine.18-4-329.Snowden J. A., Sharrack B., Akil M. et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist // Clin Med (Lond). 2018;18(4):329–334. https://doi.org/10.7861/clinmedicine.18-4-329.Poudel D. R., Derk C. T. Mortality and survival in systemic sclerosis: a review of recent literature // Curr Opin Rheumatol. – 2018. – Vol. 30, № 6. – P. 588–593. https://doi.org/10.1097/BOR.0000000000000551.Poudel D. R., Derk C. T. Mortality and survival in systemic sclerosis: a review of recent literature // Curr Opin Rheumatol. 2018;30(6):588–593. https://doi.org/10.1097/BOR.0000000000000551.Bergamasco A., Hartmann N., Wallace L., Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease // Clin Epidemiol. – 2019. – Vol. 11. – P. 257–273. https://doi.org/10.2147/CLEP.S191418.Bergamasco A., Hartmann N., Wallace L., Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease // Clin Epidemiol. 2019;11:257–273. https://doi.org/10.2147/CLEP.S191418.Tyndall A. J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database // Ann Rheum Dis. – 2010. – Vol. 69, № 10. – P. 1809– 15. https://doi.org/10.1136/ard.2009.114264.Tyndall A. J., Bannert B., Vonk M. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database // Ann Rheum Dis. 2010;69(10):1809–15. https://doi.org/10.1136/ard.2009.114264.Denton C. P., Khanna D. Systemic sclerosis // Lancet. – 2017. – Vol. 390, № 10103. – P. 1685–1699. https://doi.org/10.1016/S0140-6736(17)30933-9.Denton C. P., Khanna D. Systemic sclerosis // Lancet. 2017;390(10103):1685–1699. https://doi.org/10.1016/S0140-6736(17)30933-9.Ramaswamy S., Jain S., Ravindran V. Hematopoietic stem cell transplantation for auto immune rheumatic diseases // World J Transplant. – 2016. – Vol. 6, № 1. – P. 199–205. https://doi.org/10.5500/wjt.v6.i1.199.Ramaswamy S., Jain S., Ravindran V. Hematopoietic stem cell transplantation for auto immune rheumatic diseases // World J Transplant. 2016;6(1):199–205. https://doi.org/10.5500/wjt.v6.i1.199.Burt R. K., Traynor A., Statkute L. et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus // JAMA. – 2006. – Vol. 295, № 5. – P. 527–35. https://doi.org/10.1001/jama.295.5.527.Burt R. K., Traynor A., Statkute L. et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus // JAMA. 2006;295(5):527–35. https://doi.org/10.1001/jama.295.5.527.Oyama Y., Barr W. G., Statkute L. et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis // Bone Marrow Transplant. – 2007. – Vol. 40, № 6. – P. 549–55. https://doi.org/10.1038/sj.bmt.1705782.Oyama Y., Barr W. G., Statkute L. et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis // Bone Marrow Transplant. 2007;40(6):549–55. https://doi.org/10.1038/sj.bmt.1705782.Burt R. K., Han X., Quigley K. et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days // Bone Marrow Transplant. – 2021. – Vol. 56, № 1. – P. 50–59. https://doi.org/10.1038/s41409-020-0978-2.Burt R. K., Han X., Quigley K. et al. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days // Bone Marrow Transplant. 2021;56(1):50–59. https://doi.org/10.1038/s41409-020-0978-2.Storek J., Zhao Z., Lin E. et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) // Clin Immunol. – 2004. – Vol. 113, № 3. – P. 285–98. https://doi.org/10.1016/j.clim.2004.07.006.Storek J., Zhao Z., Lin E. et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) // Clin Immunol. 2004;113(3):285–98. https://doi.org/10.1016/j.clim.2004.07.006.Henes J., Glaeser L., Kötter I. et al. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation // Rheumatology (Oxford). – 2017. – Vol. 56, № 3. – P. 451–456. https://doi.org/10.1093/rheumatology/kew319.Henes J., Glaeser L., Kötter I. et al. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation // Rheumatology (Oxford). 2017;56(3):451–456. https://doi.org/10.1093/rheumatology/kew319.Glaeser L., Henes J., Kötter I. et al. Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation // Clin Exp Rheumatol. – 2018. – Vol. 36, Suppl 113, № 4. – P. 28–35.Glaeser L., Henes J., Kötter I. et al. Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation // Clin Exp Rheumatol. 2018;36 Suppl 113(4):28–35.Tsukamoto H., Nagafuji K., Horiuchi T. et al. Analysis of immune reconstitution after autologous CD34+ stem/ progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells // Rheumatology (Oxford). – 2011. – Vol. 50, № 5. – P. 944–52. https://doi.org/10.1093/rheumatology/keq414.Tsukamoto H., Nagafuji K., Horiuchi T. et al. Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells // Rheumatology (Oxford). 2011;50(5):944–52. https://doi.org/10.1093/rheumatology/keq414.Levin D., Osman M. S., Durand C. et al. Hematopoietic cell transplantation for systemic sclerosis-a review // Cells. – 2022. – Vol. 11, № 23. – P. 3912. https://doi.org/10.3390/cells11233912.Levin D., Osman M. S., Durand C. et al. Hematopoietic Cell Transplantation for Systemic Sclerosis-A Review // Cells. 2022;11(23):3912. https://doi.org/10.3390/cells11233912.Gernert M., Tony H. P., Schwaneck E. C. et al. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern // Arthritis Res Ther. – 2019. – Vol. 21, № 1. – P. 106. https://doi.org/10.1186/s13075-019-1889-8.Gernert M., Tony H. P., Schwaneck E. C. et al. Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern // Arthritis Res Ther. 2019;21(1):106. https://doi.org/10.1186/s13075-019-1889-8.Sullivan K. M., Shah A., Sarantopoulos S., Furst D. E. Review: Hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement // Arthritis Rheumatol. – 2016. – Vol. 68, № 10. – P. 2361–71. https://doi.org/10.1002/art.39748.Sullivan K. M., Shah A., Sarantopoulos S., Furst D. E. Review: Hematopoietic stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement // Arthritis Rheumatol. 2016; 68(10):2361–71. https://doi.org/10.1002/art.39748.Burt R. K., Shah S. J., Dill K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial // Lancet. – 2011. – Vol. 378, № 9790. – P. 498–506. https://doi.org/10.1016/S0140-6736(11)60982-3.Burt R. K., Shah S. J., Dill K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial // Lancet. 2011;378(9790):498–506. https://doi.org/10.1016/S0140-6736(11)60982-3.van Laar J. M., Farge D., Sont J. K. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis. – P. a randomized clinical trial // JAMA. – 2014. – Vol. 311, № 24. – P. 2490–8. https://doi.org/10.1001/jama.2014.6368.van Laar J. M., Farge D., Sont J. K. et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial // JAMA. 2014;311(24):2490–8. https://doi.org/10.1001/jama.2014.6368.Sullivan K. M., Goldmuntz E. A., Keyes-Elstein L. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma // N Engl J Med. – 2018. – Vol. 378, № 1. – P. 35–47. https://doi.org/10.1056/nejmoa1703327.Sullivan K. M., Goldmuntz E. A., Keyes-Elstein L. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma // N Engl J Med. 2018;378(1):35–47. https://doi.org/10.1056/nejmoa1703327.Atkins H. L., Muraro P. A., van Laar J. M., Pavletic S.Z. Autologous hematopoietic stem cell transplantation for autoimmune disease – is it now ready for prime time? // Biol Blood Marrow Transplant. – 2012. – Vol. 18, № 1 Suppl. – P. S177–83. https://doi.org/10.1016/j.bbmt.2011.11.020.Atkins H. L., Muraro P. A., van Laar J. M., Pavletic S. Z. Autologous hematopoietic stem cell transplantation for autoimmune disease – is it now ready for prime time? // Biol Blood Marrow Transplant. 2012;18(1 Suppl):S177–83. https://doi.org/10.1016/j.bbmt.2011.11.020.Del Papa N., Onida F., Zaccara E. et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis // Bone Marrow Transplant. – 2017. – Vol. 52, № 1. – P. 53–58. https://doi.org/10.1038/bmt.2016.211.Del Papa N., Onida F., Zaccara E. et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis // Bone Marrow Transplant. 2017;52(1):53–58. https://doi.org/10.1038/bmt.2016.211.Del Papa N., Cavalli S., Rindone A. et al. Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents // Arthritis Res Ther. – 2024. – Vol. 26, № 1. – P. 182. https://doi.org/10.1186/s13075-024-03408-4.Del Papa N., Cavalli S., Rindone A. et al. Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents // Arthritis Res Ther. 2024;26(1):182. https://doi.org/10.1186/s13075-024-03408-4.Zare Moghaddam M., Mousavi M. J., Ghotloo S. Stem cell-based therapy for systemic sclerosis // Rheumatol Adv Pract. – 2023. – Vol. 7, № 3. – P. rkad101. https://doi.org/10.1093/rap/rkad101.Zare Moghaddam M., Mousavi M. J., Ghotloo S. Stem cell-based therapy for systemic sclerosis // Rheumatol Adv Pract. 2023;7(3):rkad101. https://doi.org/10.1093/rap/rkad101.Del Papa N., Pignataro F., Zaccara E. et al. Autologous Hematopoietic Stem Cell Transplantation for Treatmentof Systemic Sclerosis // Front Immunol. – 2018. – Vol. 9. – P. 2390. https://doi.org/10.3389/fimmu.2018.02390.Del Papa N., Pignataro F., Zaccara E. et al. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis // Front Immunol. 2018;9:2390. https://doi.org/10.3389/fimmu.2018.02390.Hosing C., Nash R., McSweeney P. et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States // Biol Blood Marrow Transplant. – 2011. – Vol. 17, № 5. – P. 674–81. https://doi.org/10.1016/j.bbmt.2010.08.003.Hosing C., Nash R., McSweeney P. et al. Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States // Biol Blood Marrow Transplant. 2011;17(5):674–81. https://doi.org/10.1016/j.bbmt.2010.08.003.Guillaume-Jugnot P., Badoglio M., Labopin M. et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) // Clin Rheumatol. – 2019. – Vol. 38, № 5. – P. 1501–1511. https://doi.org/10.1007/s10067-019-04435-2.Guillaume-Jugnot P., Badoglio M., Labopin M. et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) // Clin Rheumatol. 2019;38(5):1501–1511. https://doi.org/10.1007/s10067-019-04435-2.Strunz P. P., Froehlich M., Gernert M. et al. Immunological adverse events after autologous hematopoietic stem cell transplantation in systemic sclerosis patients // Front Immunol. – 2021. – Vol. 12. – P. 723349. https://doi.org/10.3389/fimmu.2021.723349.Strunz P. P., Froehlich M., Gernert M. et al. Immunological adverse events after autologous hematopoietic stem cell transplantation in systemic sclerosis patients // Front Immunol. 2021;12:723349. https://doi.org/10.3389/fimmu.2021.723349.Daikeler T., Labopin M., Di Gioia M. et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party // Blood. – 2011. – Vol. 118, № 6. – P. 1693–8. https://doi.org/10.1182/blood-2011-02-336156.Daikeler T., Labopin M., Di Gioia M. et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party // Blood. 2011;118(6):1693–8. https://doi.org/10.1182/blood-2011-02-336156.Henes J. C., Schmalzing M., Vogel W. et al. Optimization of autologous stem cell transplantation for systemic sclerosis - a single-center longterm experience in 26 patients with severe organ manifestations // J Rheumatol. – 2012. – Vol. 39, № 2. – P. 269–75. https://doi.org/10.3899/jrheum.110868.Henes J. C., Schmalzing M., Vogel W. et al. Optimization of autologous stem cell transplantation for systemic sclerosis – a single-center longterm experience in 26 patients with severe organ manifestations // J Rheumatol. 2012;39(2):269–75. https://doi.org/10.3899/jrheum.110868.Kowal-Bielecka O., Fransen J., Avouac J. et al. Update of EULAR recommendations for the treatment of systemic sclerosis // Ann Rheum Dis. – 2017. – Vol. 76, № 8. – P. 1327–1339. https://doi.org/10.1136/annrheumdis-2016-209909.Kowal-Bielecka O., Fransen J., Avouac J. et al. Update of EULAR recommendations for the treatment of systemic sclerosis // Ann Rheum Dis. 2017;76(8):1327–1339. https://doi.org/10.1136/annrheumdis-2016-209909.Burt R. K., Farge D. Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer? // Nat Rev Rheumatol. – 2018. – Vol. 14, № 4. – P. 189–191. https://doi.org/10.1038/nrrheum.2018.34.Burt R. K., Farge D. Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer? // Nat Rev Rheumatol. 2018;14(4):189–191. https://doi.org/10.1038/nrrheum.2018.34.Snowden J. A., Badoglio M., Labopin M. et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases // Blood Adv. – 2017. – Vol. 1, № 27. – P. 2742–2755. https://doi.org/10.1182/bloodadvances.2017010041.Snowden J. A., Badoglio M., Labopin M. et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases // Blood Adv. 2017;1(27):2742–2755. https://doi.org/10.1182/bloodadvances.2017010041.Domsic R. T., Rodriguez-Reyna T., Lucas M. et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma // Ann Rheum Dis. – 2011. – Vol. 70, № 1. – P. 104–9. https://doi.org/10.1136/ard.2009.127621.Domsic R. T., Rodriguez-Reyna T., Lucas M. et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma // Ann Rheum Dis. 2011;70(1):104–9. https://doi.org/10.1136/ard.2009.127621.Maurer B., Graf N., Michel B. A. et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database // Ann Rheum Dis. – 2015. – Vol. 74, № 6. – P. 1124–31. https://doi.org/10.1136/annrheumdis-2014-205226.Maurer B., Graf N., Michel B. A. et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database // Ann Rheum Dis. 2015;74(6):1124–31. https://doi.org/10.1136/annrheumdis-2014-205226.Steen V. D., Medsger T. A. Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival // Arthritis Rheum. – 2001. – Vol. 44, № 12. – P. 2828–35. https://doi.org/10.1002/1529-0131(200112)44:12<2828::aidart470>3.0.co;2-u.Steen V. D., Medsger T. A. Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival // Arthritis Rheum. 2001;44(12):2828–35. https://doi.org/10.1002/1529-0131(200112)44:12<2828::aidart470>3.0.co;2-u.van den Hoogen F., Khanna D., Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative // Ann Rheum Dis. – 2013. – Vol. 72, № 11. – P. 1747–55. https://doi.org/10.1136/annrheumdis-2013-204424.van den Hoogen F., Khanna D., Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative // Ann Rheum Dis. 2013;72(11):1747–55. https://doi.org/10.1136/annrheumdis-2013-204424.Farge D., Ait Abdallah N., Marjanovic Z., Del Papa N. Autologous stem cell transplantation in scleroderma // Presse Med. – 2021. – Vol. 50, № 1. – P. 104065. https://doi.org/10.1016/j.lpm.2021.104065.Farge D., Ait Abdallah N., Marjanovic Z., Del Papa N. Autologous stem cell transplantation in scleroderma // Presse Med. 2021;50(1):104065. https://doi.org/10.1016/j.lpm.2021.104065.

The authors declare that there are no conflicts of interest present.